Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Immune Checkpoint Inhibtors industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
AstraZeneca PLC
Eli Lilly and Company (ARMO Biosciences)
BeiGene Ltd
Merck KGaA (EMD Serono Inc)
Merck & Co, Inc
Shanghai Jhunsi Biosciences Ltd
Sanofi
Bristol-Myers Squibb Company
GlaxoSmithKline PLC
By Type:
CTLA-4 Inhibitor
PD-L1 Inhibitors
PD-1 Inhibitors
By Application:
Hodgkin lymphoma
Bladder Cancer
Lung Cancer
Melanoma
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Immune Checkpoint Inhibtors Market Overview 2018-2029
-
1.1 China Immune Checkpoint Inhibtors Industry Development Overview
-
1.2 China Immune Checkpoint Inhibtors Industry Development History
-
1.3 China Immune Checkpoint Inhibtors Industry Market Size (2018-2029)
-
1.4 China Immune Checkpoint Inhibtors Market Analysis by Type from Production Side
-
1.4.1 China Immune Checkpoint Inhibtors Production Volume, Production Value and Growth Rate of CTLA-4 Inhibitor (2018-2029)
-
1.4.2 China Immune Checkpoint Inhibtors Production Volume, Production Value and Growth Rate of PD-L1 Inhibitors (2018-2029)
-
1.4.3 China Immune Checkpoint Inhibtors Production Volume, Production Value and Growth Rate of PD-1 Inhibitors (2018-2029)
-
1.5 China Immune Checkpoint Inhibtors Market Analysis by Application from Consumption End
-
1.5.1 China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Hodgkin lymphoma (2018-2029)
-
1.5.2 China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Bladder Cancer (2018-2029)
-
1.5.3 China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Lung Cancer (2018-2029)
-
1.5.4 China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Melanoma (2018-2029)
-
1.6 China Immune Checkpoint Inhibtors Market Analysis by Region
-
1.6.1 North China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
Chapter 2 China Immune Checkpoint Inhibtors Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Immune Checkpoint Inhibtors Market Status and Competition at home and abroad in 2023
-
2.2.2 China Immune Checkpoint Inhibtors Market Status and Competition Analysis in 2023
-
2.2.3 China Immune Checkpoint Inhibtors Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Immune Checkpoint Inhibtors Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Immune Checkpoint Inhibtors Industry Development
Chapter 3 Immune Checkpoint InhibtorsIndustry Chain Analysis
-
3.1 Immune Checkpoint Inhibtors Industry Chain
-
3.2 Immune Checkpoint Inhibtors Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Immune Checkpoint Inhibtors Market
-
3.3 Immune Checkpoint Inhibtors Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Immune Checkpoint Inhibtors Market
Chapter 4 China Immune Checkpoint Inhibtors Market, by Type
-
4.1 China Immune Checkpoint Inhibtors Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Immune Checkpoint Inhibtors Total Production Volume and Growth Rate from Production Side
-
4.5 China Immune Checkpoint Inhibtors Production Volume and Growth Rate, by Type
-
4.5.1 China Immune Checkpoint Inhibtors Production Volume and Growth Rate of CTLA-4 Inhibitor
-
4.5.2 China Immune Checkpoint Inhibtors Production Volume and Growth Rate of PD-L1 Inhibitors
-
4.5.3 China Immune Checkpoint Inhibtors Production Volume and Growth Rate of PD-1 Inhibitors
Chapter 5 China Immune Checkpoint Inhibtors Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Immune Checkpoint Inhibtors Total Market Size and Growth Rate from Consumption End
-
5.5 China Immune Checkpoint Inhibtors Market Size and Growth Rate, by Application
-
5.5.1 China Immune Checkpoint Inhibtors Market Size and Growth Rate of Hodgkin lymphoma
-
5.5.2 China Immune Checkpoint Inhibtors Market Size and Growth Rate of Bladder Cancer
-
5.5.3 China Immune Checkpoint Inhibtors Market Size and Growth Rate of Lung Cancer
-
5.5.4 China Immune Checkpoint Inhibtors Market Size and Growth Rate of Melanoma
Chapter 6 China Immune Checkpoint Inhibtors Market, by Region
-
6.1 China Immune Checkpoint Inhibtors Production Volume and Production Value, by Region
-
6.2 China Immune Checkpoint Inhibtors Sales Volume and Sales Value, by Region
Chapter 7 North China Immune Checkpoint Inhibtors Market Analysis
-
7.1 North China Immune Checkpoint Inhibtors Market, by Type
-
7.2 North China Immune Checkpoint Inhibtors Market, by Application
Chapter 8 Central China Immune Checkpoint Inhibtors Market Analysis
-
8.1 Central China Immune Checkpoint Inhibtors Market, by Type
-
8.2 Central China Immune Checkpoint Inhibtors Market, by Application
Chapter 9 South China Immune Checkpoint Inhibtors Market Analysis
-
9.1 South China Immune Checkpoint Inhibtors Market, by Type
-
9.2 South China Immune Checkpoint Inhibtors Market, by Application
Chapter 10 East China Immune Checkpoint Inhibtors Market Analysis
-
10.1 East China Immune Checkpoint Inhibtors Market, by Type
-
10.2 East China Immune Checkpoint Inhibtors Market, by Application
Chapter 11 Northeast China Immune Checkpoint Inhibtors Market Analysis
-
11.1 Northeast China Immune Checkpoint Inhibtors Market, by Type
-
11.2 Northeast China Immune Checkpoint Inhibtors Market, by Application
Chapter 12 Southwest China Immune Checkpoint Inhibtors Market Analysis
-
12.1 Southwest China Immune Checkpoint Inhibtors Market, by Type
-
12.2 Southwest China Immune Checkpoint Inhibtors Market, by Application
Chapter 13 Northwest China Immune Checkpoint Inhibtors Market Analysis
-
13.1 Northwest China Immune Checkpoint Inhibtors Market, by Type
-
13.2 Northwest China Immune Checkpoint Inhibtors Market, by Application
Chapter 14 Company Profiles
-
14.1 AstraZeneca PLC
-
14.1.1 AstraZeneca PLC Company Profile
-
14.1.2 AstraZeneca PLC Immune Checkpoint Inhibtors Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Eli Lilly and Company (ARMO Biosciences)
-
14.2.1 Eli Lilly and Company (ARMO Biosciences) Company Profile
-
14.2.2 Eli Lilly and Company (ARMO Biosciences) Immune Checkpoint Inhibtors Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 BeiGene Ltd
-
14.3.1 BeiGene Ltd Company Profile
-
14.3.2 BeiGene Ltd Immune Checkpoint Inhibtors Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Merck KGaA (EMD Serono Inc)
-
14.4.1 Merck KGaA (EMD Serono Inc) Company Profile
-
14.4.2 Merck KGaA (EMD Serono Inc) Immune Checkpoint Inhibtors Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Merck & Co, Inc
-
14.5.1 Merck & Co, Inc Company Profile
-
14.5.2 Merck & Co, Inc Immune Checkpoint Inhibtors Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 Shanghai Jhunsi Biosciences Ltd
-
14.6.1 Shanghai Jhunsi Biosciences Ltd Company Profile
-
14.6.2 Shanghai Jhunsi Biosciences Ltd Immune Checkpoint Inhibtors Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Sanofi
-
14.7.1 Sanofi Company Profile
-
14.7.2 Sanofi Immune Checkpoint Inhibtors Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Bristol-Myers Squibb Company
-
14.8.1 Bristol-Myers Squibb Company Company Profile
-
14.8.2 Bristol-Myers Squibb Company Immune Checkpoint Inhibtors Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 GlaxoSmithKline PLC
-
14.9.1 GlaxoSmithKline PLC Company Profile
-
14.9.2 GlaxoSmithKline PLC Immune Checkpoint Inhibtors Market Performance
-
14.9.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Immune Checkpoint Inhibtors Industry Research Conclusions
-
15.2 Immune Checkpoint Inhibtors Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Immune Checkpoint Inhibtors Industry Market Size (2018-2029)
-
Figure China Immune Checkpoint Inhibtors Production Volume, Production Value and Growth Rate of CTLA-4 Inhibitor (2018-2029)
-
Figure China Immune Checkpoint Inhibtors Production Volume, Production Value and Growth Rate of PD-L1 Inhibitors (2018-2029)
-
Figure China Immune Checkpoint Inhibtors Production Volume, Production Value and Growth Rate of PD-1 Inhibitors (2018-2029)
-
Figure China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Hodgkin lymphoma (2018-2029)
-
Figure China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Bladder Cancer (2018-2029)
-
Figure China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Lung Cancer (2018-2029)
-
Figure China Immune Checkpoint Inhibtors Sales Volume, Sales Value and Growth Rate of Melanoma (2018-2029)
-
Figure North China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
Figure Central China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
Figure South China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
Figure East China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Immune Checkpoint Inhibtors Market Size and Growth Rate from 2018-2029
-
Figure Immune Checkpoint Inhibtors Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Immune Checkpoint Inhibtors Market Share by Type in 2018
-
Figure China Immune Checkpoint Inhibtors Market Share by Type in 2023
-
Figure China Immune Checkpoint Inhibtors Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Production Volume and Growth Rate of CTLA-4 Inhibitor (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Production Volume and Growth Rate of PD-L1 Inhibitors (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Production Volume and Growth Rate of PD-1 Inhibitors (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Market Share by Application in 2018
-
Figure China Immune Checkpoint Inhibtors Market Share by Application in 2023
-
Figure China Immune Checkpoint Inhibtors Total Market Size and Growth Rate from Consumption End
-
Figure China Immune Checkpoint Inhibtors Market Size and Growth Rate of Hodgkin lymphoma (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Market Size and Growth Rate of Bladder Cancer (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Market Size and Growth Rate of Lung Cancer (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Market Size and Growth Rate of Melanoma (2018-2023)
-
Table China Immune Checkpoint Inhibtors Production Volume by Region (2018-2023)
-
Table China Immune Checkpoint Inhibtors Production Volume Share by Region (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Production Volume Share by Region (2018-2023)
-
Table China Immune Checkpoint Inhibtors Production Value by Region (2018-2023)
-
Table China Immune Checkpoint Inhibtors Production Value Share by Region (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Production Value Share by Region (2018-2023)
-
Table China Immune Checkpoint Inhibtors Sales Volume by Region (2018-2023)
-
Table China Immune Checkpoint Inhibtors Sales Volume Share by Region (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Sales Volume Share by Region (2018-2023)
-
Table China Immune Checkpoint Inhibtors Sales Value by Region (2018-2023)
-
Table China Immune Checkpoint Inhibtors Sales Value Share by Region (2018-2023)
-
Figure China Immune Checkpoint Inhibtors Sales Value Share by Region (2018-2023)
-
Table North China Immune Checkpoint Inhibtors Production Volume by Type (2018-2023)
-
Table North China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Figure North China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Table North China Immune Checkpoint Inhibtors Sales Volume by Application (2018-2023)
-
Table North China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Figure North China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Table Central China Immune Checkpoint Inhibtors Production Volume by Type (2018-2023)
-
Table Central China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Figure Central China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Table Central China Immune Checkpoint Inhibtors Sales Volume by Application (2018-2023)
-
Table Central China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Figure Central China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Table South China Immune Checkpoint Inhibtors Production Volume by Type (2018-2023)
-
Table South China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Figure South China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Table South China Immune Checkpoint Inhibtors Sales Volume by Application (2018-2023)
-
Table South China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Figure South China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Table East China Immune Checkpoint Inhibtors Production Volume by Type (2018-2023)
-
Table East China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Figure East China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Table East China Immune Checkpoint Inhibtors Sales Volume by Application (2018-2023)
-
Table East China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Figure East China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Table Northeast China Immune Checkpoint Inhibtors Production Volume by Type (2018-2023)
-
Table Northeast China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Figure Northeast China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Table Northeast China Immune Checkpoint Inhibtors Sales Volume by Application (2018-2023)
-
Table Northeast China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Table Southwest China Immune Checkpoint Inhibtors Production Volume by Type (2018-2023)
-
Table Southwest China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Figure Southwest China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Table Southwest China Immune Checkpoint Inhibtors Sales Volume by Application (2018-2023)
-
Table Southwest China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Table Northwest China Immune Checkpoint Inhibtors Production Volume by Type (2018-2023)
-
Table Northwest China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Figure Northwest China Immune Checkpoint Inhibtors Production Volume Share by Type (2018-2023)
-
Table Northwest China Immune Checkpoint Inhibtors Sales Volume by Application (2018-2023)
-
Table Northwest China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Immune Checkpoint Inhibtors Sales Volume Share by Application (2018-2023)
-
Table AstraZeneca PLC Company Profile
-
Table AstraZeneca PLC Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table Eli Lilly and Company (ARMO Biosciences) Company Profile
-
Table Eli Lilly and Company (ARMO Biosciences) Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table BeiGene Ltd Company Profile
-
Table BeiGene Ltd Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table Merck KGaA (EMD Serono Inc) Company Profile
-
Table Merck KGaA (EMD Serono Inc) Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table Merck & Co, Inc Company Profile
-
Table Merck & Co, Inc Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table Shanghai Jhunsi Biosciences Ltd Company Profile
-
Table Shanghai Jhunsi Biosciences Ltd Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table Sanofi Company Profile
-
Table Sanofi Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table Bristol-Myers Squibb Company Company Profile
-
Table Bristol-Myers Squibb Company Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
Table GlaxoSmithKline PLC Company Profile
-
Table GlaxoSmithKline PLC Immune Checkpoint Inhibtors Revenue, Price and Gross (2018-2023)
-
